LISA A. CONTE - 05 Apr 2022 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role
CEO and President, Director
Signature
/s/ Lisa A. Conte
Issuer symbol
JAGX
Transactions as of
05 Apr 2022
Transactions value $
$0
Form type
4
Filing time
06 Apr 2022, 16:31:36 UTC
Previous filing
30 Mar 2022
Next filing
28 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAGX Common Stock Options Exercise +45K +562.29% 53K 05 Apr 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Restricted stock units Award $0 +45K +100% $0.00 90K 05 Apr 2022 Common Stock 45K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.
F3 The restricted stock units were previously reported as covering 405,000 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date.